Du är här

2014-05-06

CellaVision AB: Yvonne Mårtensson will leave her position as President/CEO of CellaVision at year end 2014.

This information was released for public disclosure on May 6, 2014 at 8.20 am
CET.

Yvonne Mårtensson remains CEO until a successor is appointed or until 31
December 2014 at the latest. Yvonne Mårtensson has been CEO since 1998.
"I have had the privilege of being part of this exciting journey that started
sixteen years ago. Together with fantastic colleagues I was able to take
CellaVision from an invention and a few developers to an established medical
technology company with 70 employees in Europe, North America and Asia. I am
proud of having built a stable company with strong shared values, as a
platform for continued development and growth," says Yvonne Mårtensson.
Since Yvonne Mårtensson joined CellaVision as CEO in 1998 CellaVision has
progressed from being an exciting innovation company to a global market
leader in digital solutions for medical microscopy in hematology. In 2013 the
company's sales were SEK 180 million, with an operating margin of almost 15
per cent. CellaVision's products are used in some 2,000 laboratories in more
than 50 countries.
The company has been listed on Nasdaq OMX Stockholm since 2010.

"In her sixteen years as President/CEO of CellaVision Yvonne Mårtensson has
done an unprecedented job of building the company into the global medical
technology innovation company it is today. We hold a very strong position in
the business segment where we operate, based on focusing on customer
satisfaction and developing solutions that give patient benefit and
efficiencies in healthcare. With her leadership and operative skill Yvonne
has achieved deeply impressive work," says Lars Gatenbeck, Chairman of the
Board.
The work of recruiting a new President/CEO will be started and Yvonne
Mårtensson will remain in the position as CEO until a successor is in place.
She will stay in the company until the year end in order to maintain the
continuity and secure a smooth transition.

Lars Gatenbeck

Chairman of the Board
For more information, please contact:

Yvonne Mårtensson, CEO, CellaVision AB

Tel: +46708337782 | Email:yvonne.martensson@cellavision.com
About CellaVision

CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other
body fluids in health care services. The analyses often constitute important
reference data for fast and correct diagnosis of illnesses, for example of
infections and serious cancers. CellaVision's products rationalize manual
laboratory work, and secure and support effective workflows and skills
development within and between hospitals. The company has leading-edge
expertise in image analysis, artificial intelligence and automated
microscopy. In 2013 sales were SEK 180 million and sales continue to
increase, with a growth target of at least 15 % per year over an economic
cycle. CellaVision's registered office is in Lund and the company has
subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq
OMX Stockholm, Small Cap list. Read more atwww.cellavision.com.

Press release as PDF
http://hugin.info/132164/R/1782894/610402.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire

HUG#1782894

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.